Klotho Neurosciences, Inc.
NASDAQ: KLTO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph A. Sinkule
- Employees
- 3
- Headquarters
- Omaha, United States
- IPO year
- 2022
- Market cap
- $20.1M
- Website
- https://klothoneuro.com
Loading KLTO…
Loading profile data…Frequently asked questions about KLTO
What does Klotho Neurosciences, Inc. (KLTO) do?
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-20...
Where does KLTO trade?
Klotho Neurosciences, Inc. (KLTO) trades on the NASDAQ Global Market.
What sector is KLTO in?
Klotho Neurosciences, Inc. (KLTO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Klotho Neurosciences, Inc.?
Joseph A. Sinkule is the chief executive officer of Klotho Neurosciences, Inc. (KLTO).
Where is Klotho Neurosciences, Inc. headquartered?
Klotho Neurosciences, Inc. is headquartered in United States.
Does KLTO pay a dividend?
Klotho Neurosciences, Inc. (KLTO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KLTO go public?
Klotho Neurosciences, Inc. (KLTO) completed its initial public offering in 2022.